ABSTRACT
Castleman's disease in the parotid gland region is very rare. The most frequent site of involvement is the mediastinum. A 15-year-old female with Castleman's disease in the parotid region is herein reported.
Subject(s)
Castleman Disease/pathology , Castleman Disease/surgery , Parotid Diseases/pathology , Parotid Diseases/surgery , Adolescent , Female , HumansABSTRACT
Esta página es una base de datos sobre compatibilidad de las medicaciones, fitoterapia, tóxicos (tabaco, drogas...) así como enfermedades del niño o de las madres que dan lactancia materna. Para profesionales de la salud
Subject(s)
52503 , Pediatrics , Complementary Therapies , Pharmaceutical Preparations , Pharmacy , Breast FeedingSubject(s)
Hydatidiform Mole/diagnosis , Pregnancy, Multiple , Abortion, Therapeutic , Adolescent , Female , Humans , Hydatidiform Mole/surgery , Pregnancy , TwinsABSTRACT
There is currently substantial clinical interest in growth hormone (GH) as a protective agent against radiation-related normal tissue injury. To further assess the potential radiation injury-preventive effects of GH, these effects were studied in rats by using a radiation-induced skin injury model. Group 1 received neither GH nor irradiation (control group). Group 2 received 30 Gy of gamma irradiation as a single dose to the right hind legs of the rats (radiation group). Group 3 and 4 received the same irradiation plus either 0.01 U/kg/day GH (RT + 0.01 GH group) or 0.02 U/kg/day GH (RT + 0.02 GH group) subcutaneously. Clinically and histopathologically, acute skin reactions were assessed by two independent experts in radiation oncology and pathology, respectively. Irradiation increased dermatitis in rats when compared with the control group. The severity of radiodermatitis in the rats in the RT + 0.01 GH and RT + 0.02 GH groups was significantly lower than that in the RT group; radiodermatitis developed earlier in the RT group than in the other groups. GH was efficacious in preventing epidermal atrophy, dermal degeneration such as oedema and collagen fibre loss, and hair follicle atrophy, but not better than in the control group. These results are preliminary to studies that will be performed with higher doses of GH in radiation-treated cancer patients, with the aim of reducing radiation-induced toxicity.
Subject(s)
Growth Hormone/administration & dosage , Radiation Injuries, Experimental/prevention & control , Radiation-Protective Agents/administration & dosage , Radiodermatitis/prevention & control , Animals , Disease Models, Animal , Gamma Rays/adverse effects , Injections, Subcutaneous , Male , Radiation Dosage , Radiation Injuries, Experimental/etiology , Radiation Injuries, Experimental/pathology , Radiodermatitis/etiology , Radiodermatitis/pathology , Rats , Rats, Sprague-Dawley , Skin/pathology , Skin/radiation effectsABSTRACT
The aim of this paper was to investigate the protective effect of the T-type calcium channel blocker in a model of acute local inflammation (histamine-induced). The intraplantar injection of histamine elicited an inflammatory response that was characterized by a time-dependent increase in paw oedema and neutrophil infiltration in paw tissue. The maximal increase in paw volume was observed at 90 min after histamine administration (maximal paw volume: 0.97 +/- 0.07). In addition, polymorphonuclear leucocyte (PNL) number was markedly increased in the histamine-treated paw tissue (144 +/- 25.56). However, histamine-induced paw oedema was significantly reduced in a dose-dependent manner by treatment with mibefradil (given at 10, 25, 50, and 100 mg x kg(-1)) at 30, 60, 90, 120, 150, 180 min after injection of histamine. Mibefradil treatment also caused a significant reduction of the polymorphonuclear leucocyte number in the paw tissue. Our findings support the view that mibefradil exerts antiinflammatory effects.
